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A BST R A C T 
Frontotemporal lobar degeneration with neuronal inclusions containing TDP-43 protein 
is associated in most cases with null-mutations in the progranulin gene (PGRN). While 
the mechanisms by which PGRN haploinsufficiency leads to neurodegeneration 
remained speculative, increasing evidence support the hypothesis that cell cycle reentry 
of postmitotic neurons precedes many instances of neuronal death. Based in the 
mitogenic and neurotrophic activities of PGRN, we hypothesized that PGRN deficit 
may induce cell cycle disturbances and alterations in neuronal vulnerability. Since cell 
cycle dysfunction is not restricted to neurons, we studied the influence of PGRN 
haploinsufficiency, on cell cycle control in peripheral cells from patients suffering from 
frontotemporal dementia, bearing the PGRN mutation c.709-1G>A. Here we show that 
progranulin deficit increased cell cycle activity in immortalized lymphocytes. This 
effect was associated with increased levels of CDK6 and phosphorylation of pRb, 
resulting in a G1/S regulatory failure. A loss of function of TDP-43 repressing CDK6 
expression may result from altered subcellular TDP-43 distribution. The distinct 
functional features of lymphoblastoid cells from c.709-1 G>A carriers offer an 
invaluable, noninvasive tool to investigate the etiopathogenesis of frontotemporal lobar 
degeneration 
 
 
 
 
 
 
  3 
IN T R O DU C T I O N 
Frontotemporal lobar degeneration (FTLD) is now a widely recognized form of dementia, 
characterized by gradual, progressive changes in behavior, personality and/or language 
with early preservation of memory (Ikeda et al., 2004). It is responsible for at least 20% 
of presenil cases (Neary et al., 2000). This heterogeneous disease has been of particular 
interest to geneticists due to its high rate of heritability with up to 40% of patients 
reporting a family history of the disease in at least one extra family member. 
The main clinical presentations of FTLD are 1) behavioural bv-FTD, with disinhibition 
and changes in personality, such as apathy and poor judgment and 2) language, with a 
nonfluent aphasia with anomia (primary progressive aphasia, PPA), or a fluent aphasia 
with early loss of word meaning (semantic dementia, SD). 
Pathologically, these diseases share deposits of abnormal proteins in neuroectodermic 
cells, and severe cell loss with atrophy of vulnerable cortical and subcortical structures 
(Mackenzie et al., 2006). The most common pathology in FTLD, accounting for 40-65% 
of cases, has found to be neuritis, neuronal cytoplasmic inclusions, and lentiform 
intranuclear inclusions, containing as the major component the TAR DNA binding 
protein 43 (TDP-43) (Arai et al., 2006; Neumann et al., 2006), and thus named FTLD-
TDP (Mackenzie et al., 2010a). Four different patterns of TDP-43 pathology are 
recognized in FTLD-TDP, based on the anatomical distribution, morphology, and relative 
proportion of distinct types of inclusions. (Mackenzie et al., 2010b). This heterogeneity is 
also supported by different clinical and genetic features. The FTLD-TDP includes the 
behavioral variant FTD (bv-FTD), PPA and FTD with motor neuron disease (FTD-MND) 
(Bugiani, 2007). The next largest group of FTLD cases comprises FTLD with tau-
positive pathology (FTLD-tau) (Kumar-Singh and Van Broeckhoven, 2007), and these 
patients can present atypical parkinsonism in addition to bv-FTD and PPA. Recently 
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another small group of cases has been described to be immunoreactive for FUS (FTLD-
FUS) mutations of which have been associated with amyotrophic lateral sclerosis (ALS) 
(Kwiatkowski et al., 2009; Vance et al., 2009).  The overlap between ALS and FTD, as 
well as the homology of FUS and TDP-43 prompted a number of studies that 
demonstrated that the inclusions of the several tau/TDP-43 negative FTLDs were 
immunoreactive for FUS (Muñoz et al., 2009; Neuman et al. 2009), including the 
formerly designed FTLD-UPS because the inclusions were detected with antibodies anti 
proteins of the ubiquitin proteasome system (UPS) (Mackenzie et al., 2010a).  
 Mutations in the progranulin gene (PGRN) have been identified as the major cause of 
FTLD-TDP (Baker et al., 2006; Cruts et al., 2006). All cases of PGRN mutations are 
recognized as the subtype 1 of FTLD-TDP (Mackenzie et al., 2010b), with most frequent 
presentations of bv-FTD and PPA (Mackenzie et al., 2010b).  Up to now more than 60 
different mutations in PGRN have been described associated with the etiology of the 
disease (http://www.molgen.ua.ac.be/FTDmutations/) (Gijselinck et al., 2008). We have 
recently described a prevalent ancestral c.709-1G>A mutation related to Basque 
population (Lopez de Munain et al., 2008; Moreno et al., 2009). The c.709-1G>A 
mutation results in null allele, as most of the pathogenic mutation described up to now, 
suggesting that FTLD in these families results from PGRN haploinsufficiency (Baker et 
al., 2006). 
The biological functions of PGRN in the CNS have not been very well studied, and the 
mechanisms by which PGRN haploinsufficiency leads to neurodegeneration in FTLD 
remained speculative. PGRN is expressed in neurons and microglia (Ahmed et al., 2007). 
Some data suggests that PGRN may function as an autocrine neuronal growth factor. For 
instance, the addition of low concentrations of PGRN can promote mitogenesis in PC12 
cells (Zhou et al., 1993). In addition, a possible role for PGRN in CNS inflammation has 
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been proposed (Ahmed et al., 2007; Eriksen and Mackenzie, 2008). On these grounds, it 
seems plausible that neurodegeneration may result from reduced neuronal growth support 
or protection (Mackenzie, 2007; Neumann et al., 2007). 
Studies carried out during last decade have highlighted the important role that cell cycle 
dysfunction may play in the instigation and progression of neurodegeneration (Wishart et 
al., 2006). Neuronal changes supporting alterations in cell cycle control in the etiology of 
neurodegenerative disorders include the ectopic expression of markers of the cell cycle, 
organelle kinesis, and DNA replication (Copani et al., 2001; Herrup et al., 2004; Zhu et 
al., 2004). Aberrant induction of cell cycle regulators in postmitotic neurons have been 
reported in several neurodegenerative diseases such as Alzheimer’s disease (AD), ALS, 
and Parkinson’s disease (PD) (Arendt, 2003; Mosch et al., 2007; Yang et al., 2001). Little 
is known about the involvement of cell cycle-related events in the neurodegenerative 
process in FTLD. However, it was previously reported (Husseman et al., 2000) the 
presence of mitotic markers in the frontal cortex of two individuals diagnosed FTLD-17 
from the Seattle BK Family carrying the Val279Met tau mutation. These authors also 
reported changes in cell cycle regulatory proteins in other FTLD-tau diseases such as 
Corticobasal degeneration (CBD) or Pick disease (Husseman et al., 2000)  
A recent report has suggested a possible link between FTLD-TDP and altered cell cycle 
control (Ayala et al., 2008). Loss of functional nuclear TDP-43 as the consequence of 
accumulation of the protein in cytoplasm, leads to increased cyclin/CDK activity and 
retinoblastoma protein phosphorylation (pRb), which is a major determinant for G1 
progression (Weinberg, 1995). 
The main goal of this work has been to study the influence of PGRN haploinsufficiency 
in cell cycle regulation of peripheral blood cells, which are easily accessible, from c.709-
1G>A PGRN mutation carriers (PGRN+ cells). To this end, we have analyzed the 
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proliferative activity of lymphoblasts from patients as well as from asymptomatic c.709-
1G>A carriers and control subjects. Although FTLD symptoms reflect preferential 
neuronal loss in specific brain regions, PGRN is expressed in almost all tissues, so 
abnormalities outside the brain might be expected. In fact it is known that PGRN is 
highly expressed in peripheral blood cells (Coppola et al., 2008) and deficit of PGRN 
mRNA and/or protein levels, had been detected in lymphocytes from PGRN mutation 
carriers (Coppola et al., 2008; Finch et al., 2009; Lopez de Munain et al., 2008). The 
lymphoblastoid cell lines, obtained by infecting peripheral blood mononuclear cells with 
the Epstein Barr virus (EBV), resemble activated B cells in the expression of activation 
markers and adhesion molecules (Wang et al., 1990). EBV-immortalized lymphocytes 
retain the cellular response of fresh obtained lymphocytes, to serum addition or 
withdrawal. We found similar changes in cell proliferation and survival, as well as in the 
content of certain regulatory proteins, in these cell lines than untransformed lymphocytes 
(Bartolome et al., 2007; Munoz et al., 2008), suggesting the usefulness of this 
experimental model particularly to study cell cycle-related events associated to 
neurodegeneration (de las Cuevas et al., 2005; de las Cuevas et al., 2003). 
We report here a serum-mediated enhancement of proliferation of lymphoblasts from 
c.709-1G>A carriers, whether or not they have developed dementia. The increased cell 
proliferation is associated with increased pRb phosphorylation and CDK6 content. In 
addition, PGRN+ lymphoblasts show altered subcellular distribution of the TDP-43 
protein. The decrease in nuclear TDP-43 in PGRN+ cells may provide an explanation for 
the increased levels of CDK6 and progression of these cultures through the cell cycle.  
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M E T H O DS 
 
Cell lines 
A total of 28 individual were enrolled in this study: 18 carriers of the c.709-1G>A 
PGRN gene mutation, 6 of them patients of FTLD and 12 asymptomatic, and 10 control 
individuals without mutation in PGRN nor any sign of neurological degeneration. 
Asymptomatic and control individuals were relatives of patients. All patients were 
diagnosed as FTD in the Donostia Hospital by applying consensus criteria as published 
elsewhere (McKhann et al., 2001). Patients exhibited variable phenotype initial 
symptoms. Four of them presented the behavioral variant of frontotemporal dementia 
(bv-FTD), one progressive nonfluent aphasia, and corticobasal basal syndrome (CBS) 
the other. Patients developed a relatively rapidly progressive dementia with features that 
led to a secondary diagnosis. Notably, this secondary diagnosis was CBS in three of the 
bv-FTD cases. A summary of demographic characteristics of all subjects enrolled in this 
study is reported in Table I. 
The PGRN levels in plasma were strongly reduced in affected and unaffected subjects 
carrying the c.709-1G>A mutation (45±15 ng/ml as compared with a mean value of 140 
ng/ml for control individuals (Alzualde et al., unpublished results) 
All study protocols were approved by the Donostia Hospital and the Spanish Council of 
Higher Research Institutional Review Board and are in accordance with National and 
European Union Guidelines. In all cases, peripheral blood samples were taken after 
written informed consent of the patients or their relatives to determine the presence of 
the c.709-1G>A PGRN mutation and to establish the lymphoblastoid cell lines. 
DNA was extracted from blood cells using standard procedures. PGRN gene 
sequencing procedures used at our laboratory have been published elsewhere (Lopez de 
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Munain et al., 2008). For determination of progranulin plasma levels we used an ELISA 
kit (AdipoGene, Korea). 
Establishment of lymphoblastic cell lines was performed in our laboratory as previously 
described (Ibarreta et al., 1998) by infecting peripheral blood lymphocytes with the 
Epstein Barr virus (EBV) (Koistinen, 1987). Cells were grown in suspension in T flasks 
in an upright position, in approximately 10 ml of RPMI-1640 (Invitrogen) medium that 
contained 2 mM L-glutamine, 100 mg/ml penicillin/streptomycin and, unless otherwise 
stated, 10 % (v/v) fetal bovine serum (FBS) and maintained in a humidified 5% CO2 
incubator at 37 oC. Fluid was routinely changed every two days by removing the 
medium above the settled cells and replacing it with an equal volume of fresh medium.  
Determination of cell proliferation 
Proliferation was determined by cell counting in a Neubauer chamber. EBV 
immortalized lymphocytes from control and PGRN mutation carriers were seeded at an 
initial cell concentration of 1 x 106 cells x ml-1. Cells were enumerated everyday 
thereafter. Potential toxicity of the reagents used was routinely checked by trypan blue 
exclusion under inverted phase-contrast microscopy. 
Cell cycle analysis 
Exponentially growing cultures of cell lines were seeded at an initial concentration of 1 
x 106 cells x ml-1. Cell cycle analysis was performed using a standard method (Krishan, 
1975). Cells were fixed in 75% ethanol for 1 h at room temperature. Subsequent 
centrifugation of the samples was followed by incubation of cells in PBS containing 1 
mg/ml of RNase at room temperature for 20 min and staining with propidium iodide 
(PI; 25 mg/ml). Cells were analyzed in an EPICS-XL cytofluorimeter (Coulter 
Científica, Móstoles, Spain). Estimates of cell cycle phase distributions were obtained 
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by computer analysis of DNA content distributions. 
Immunological analysis 
Cell extracts 
To prepare whole cell extracts, cells were harvested, washed in PBS and then lysed in 
ice-cold lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 50 mM NaF, 1% Nonidet P-
40), containing 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM sodium 
pyrophosphate and protease inhibitor Complete Mini Mixture (Roche, Mannhein).  
Cytosolic and nuclear proteins were differentially extracted by lysing cells in ice-cold 
hypotonic buffer (10 mM Hepes, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 
1 mM DTT) containing 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM sodium 
pyrophosphate, and protease inhibitor mixture. After extraction on ice for 15 min, 0.5 % 
Nonidet P-40 was added, and the lysed cells centrifuged at 4000 rpm for 10 min. 
Supernatants containing cytosolic proteins were centrifuged at 13000 rpm for 10 min. 
Nuclei were washed twice with the hypotonic buffer, and then lysed in hypertonic 
buffer (20 mM Hepes, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT) 
containing 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM sodium pyrophosphate 
and protease inhibitor mixture. After extraction on ice for 30 min, the samples were 
centrifuged at 15000 rpm for 15 min at 4ºC. Antibodies to -tubulin and to lamin B1 
were used to assess the purity of the fractions. 
The protein content of the extracts was determined by the Bio-Rad protein assay kit 
(Bio-Rad Laboratories, Richmond, CA) 
Western blot analysis 
50-100 g of protein from cell extracts were fractionated on a SDS polyacrylamide gel, 
and transferred to PVDF membrane (Immobilon-P). The amount of protein and the 
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integrity of transfer were verified by staining with Ponceau-S solution (Sigma). The 
membranes were then blocked with non-fat milk and incubated, overnight at 4ºC, with 
primary antibodies at the following dilutions: 1:500 anti-pRb, 1:500 anti-CDK2, 1:500 
anti-CDK4, 1:200 anti-CDK6, 1:500 anti cyclin E, 1:1000 anti cyclin D1, 1:100 anti-
cyclin D2, 1:2000 anti-cyclin D3, 1:500 anti-p27, 1:500 anti-p21, 1:500 anti-p16, 1:200 
anti-p18, 1:500 anti-TDP-43, 1:2000 -actin, and 1:1000 anti-lamin . Signals from 
the primary antibodies were amplified using species-specific antisera conjugated with 
horseradish peroxidase (Sigma) and detected with a chemiluminiscent substrate 
detection system ELC (Amersham). The relative protein levels were determined by 
scanning the bands with a GS-800 imaging densitometer provided with the Quantity 
One 4.3.1 software from BioRad. 
 
Confocal laser scanning microscopy 
Immortalyzed lymphocytes from control and c.709-1G>A carriers individuals were 
seeded at an initial density of 1 x 106 x ml-1 and incubated in RPMI medium containing 
10% FBS for 48 h.  
Cells were fixed for 15 min in 4% paraformaldehyde in PBS, and blocked and 
permeabilized with 0.5% TritonX-100 in PBS-0.5% BSA for 20 min at room 
temperature. Then, cells were incubated with anti-TDP43 polyclonal antibody (Protein 
Tech Group, Chicago IL, USA). After washing with PBS, cells were incubated with 
Alexa Fluor 488-conjugated anti-rabbit antibody. When indicated, Alexa Fluor 568 
conjugated to phalloidin was added to simultaneously visualize F-actin. For nuclear 
staining, samples were incubated with DAPI (Sigma) at 4 mg/ml in PBS for 15min at 
room temperature. The preparations were mounted on FluorSave reagent (Calbiochem) 
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and visualizad with the Leica TCS-SP2-AOBS confocal microscope system 
(Heidelberg, Germany). 
Statistical analysis 
 Unless  otherwise  stated,  all  data  represent means   standard  error  of  the mean  (SE). 
Statistical  analysis  was  performed  on  the  Data  Desk  package  (version  4.0)  for 
Macintosh.  Statistical  significance  was  estimated  by  the  Student’s  t­test  or,  when 
appropriated, by analysis of variance (ANOVA) followed by the Fischer’s LSD test for 
multiple comparisons. Differences were considered significant at a level of p< 0.05. 
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R ESU L TS 
Proliferative activity of lymphoblasts f rom control and PG RN+ individuals. 
Fig. 1A shows a time-course analysis of the proliferative activity of lymphoblasts from 
control and c.709-1G>A carriers, both asymptomatic and FTLD affected cases. For 
these experiments, cells were seeded at an initial density of 1 x 106 cells x ml-1 in the 
presence of 10% FBS and counted for three days thereafter. Cell counts of c.709-1G>A 
carriers were significantly higher than those from normal individuals the first day after 
seeding (p<0.05), and the increased rate was maintained along 3 days of experiment. No 
differences were observed between cells from asymptomatic or patients. Fig. 1B depicts 
scatter plot of the proliferative activity of the lymphoblastoid cell lines used in this 
study 72 h after serum stimulation.  
Cell cycle disturbances in neurodegenerative disorders appear to involve a G1/S 
checkpoint failure (Nagy, 2007). For this reason, we find it interesting to determine the 
cell cycle status of lymphoblasts from control or c.709-1G>A carriers, either 
asymptomatic or FTLD patients, after 36 h of serum stimulation. As shown in Fig. 2, 
the proportion of cells in G1 phase was significantly lower and the proportion of cells in 
S phase was significantly higher in PGRN+ cells than those in control cells, 36 h after 
of serum stimulation. Again, no differences in cell cycle distribution were found 
between lymphoblasts from asymptomatic or FTLD patients (Fig. 2). On the other hand 
we did not observed significant changes in the proportion of sub-G0/G1 hypodiploid 
cells, characteristic of apoptosis/necrosis among the groups (Fig. 2), suggesting that the 
increased cell number in cultures of c.709-1G>A carriers, truly reflects an increase in 
cell proliferation.  
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Expression of key cell cycle regulatory proteins in control and PG RN+ 
lymphoblasts. 
Passage through the restriction point in late G1 and commitment to DNA synthesis are 
controlled by the presence and phosphorylation status of pRb (Draetta, 1994; Weinberg, 
1995). Hypo- and hyperphosphorylated forms of this protein are easily distinguished in 
SDS-polyacrylamide gels. Fig. 3 shows the phosphorylation status of pRb in control and 
PGR+ lymphoblasts 48 h after serum stimulation. It is observed an increase in pRb 
phosphorylation in PGRN+ cells, as evidenced by the higher intensity of the slower 
migrating band (Fig. 3). 
The phosphorylation of pRb is mediated by the cyclin-dependent kinases CDK4/CDK6-
cyclin D1 and CDK2-cyclin E (Lundberg and Weinberg, 1998; Mittnacht, 1998). As 
shown in Fig. 4 no differences were observed in the protein levels of cyclins E, D2 and 
D3 between control or PGRN+ cells. The levels of cyclin D1 were barely detectable in 
these cell cultures (Fig. 4). Fig 5 shows the cellular content of CDKs.  While CDK2 and 
CDK4 levels were similar in control and PGRN+ lymphoblasts, we detected a 
significant increase in CDK6 was found in both PGRN+ cells from asymptomatic or 
FTLD patients (Fig. 5). We then analyzed the cellular content of the members of 
Cip/Kip or the INK4 family of CDKs inhibitors in control and PGRN+ cells. Results are 
summarized in Fig. 6. We did not observe differences on either p21 or p27 content 
between control and PGRN+ cells. Neither we found differences on the INK members, 
p16 and p18 (Fig. 6).  Taken together, these observations suggest that the increased pRb 
phosphorylation in PGRN+ lymphoblasts may depend on CDK6 activity.  
To further analyze the involvement of CDK6 activity on the enhanced proliferation of 
lymphoblasts bearing the c.709-1G>A PGRN mutation, use was made of the CDK6 
inhibitor sodium butyrate (Kim et al., 2007). As shown in Fig. 7A, treatment of PGRN+ 
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lymphoblasts with increasing concentrations of sodium butyrate resulted in a significant 
inhibition of cell proliferation in a dose-dependent manner. Sodium butyrate did not 
change the proliferation of lymphoblasts from control individuals. We next evaluated 
the effect of 10M sodium butyrate on the cellular levels of CDK6. As shown in 
Fig.7B, treatment of PGRN+ cells with sodium butyrate decreased the content of the 
CDK6 protein to levels similar to those of control cells. As expected, sodium butyrate 
was able to decrease the phosphorylation status of pRb in lymphoblasts from PGRN+ 
subjects (Fig.7B). 
Subcellular distr ibution of T DP-43. 
It has been recently reported that TDP-43, the main protein in the ubiquitin+ inclusions 
in FTLD brains, negatively regulates the expression of CDK6 (Ayala et al., 2008). On 
these grounds, we considered the possibility of a loss of function of TDP-43 secondary 
to changes in the nuclear content of this protein. For this reason, we studied whether 
there are changes in the subcellular distribution of TDP-43 in PGRN+ cells. To this end 
control and PGRN+ lymphoblasts were processed for immunostaining and confocal 
laser scanning microscopy or fractionated to enrich for nuclear or cytoplasmatic 
proteins. In agreement with previous report (Buratti and Baralle, 2009), TDP-43 
predominantly localizes in the nucleus (Fig. 8A), although low levels of TDP-43 are 
observed in the cytosol. The western blot analysis of nuclear and cytoplasmic proteins 
reveled in PGRN+ cells, a small, but statistically significant, increase in the cytosolic 
content of TDP-43 that paralleled the decrease in nuclear levels of TDP-43   (Fig. 8B). 
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DISC USSI O N 
 
Accumulating evidence suggests that activation of cell cycle machinery contributes to 
neuronal dysfunction, and eventual neurodegeneration (Wishart et al., 2006). A cohort 
of neurodegenerative conditions that present cell cycle alterations have been identified. 
These include AD, PD, ALS and others (Appert-Collin et al., 2006; Hoglinger et al., 
2007). So far, cell cycle disturbances associated with FTLD have been reported for a 
number of FTLD-tau cases, including carriers of tau mutations or patients bearing tau 
inclusions (Husseman et al., 2000). Since these disorders are triggered by different 
etiologic factors, it is suggested that cell cycle activation may be the cellular response to 
different insults, and alterations of cell cycle regulatory proteins could be a convergent 
mechanism to neurodegeneration. Previous work from our and other laboratories 
(Bartolome et al., 2007; de las Cuevas et al., 2005; de las Cuevas et al., 2003; Muñoz et 
al., 2008; Nagy et al., 2002; Zhou and Jia, 2010) had demonstrated that cell cycle-
related events can be detected outside the central nervous system i.e. in peripheral blood 
lymphocytes, suggesting, therefore, that these easily accessible cells may represent 
useful tools to study the mechanisms involved in the pathogenesis of neurodegenerative 
diseases.  
In this study, we have examined the cellular response to serum stimulation of 
lymphoblasts derived from control and individuals carrying the c.709-1G>A PGRN 
mutation, either asymptomatic or diagnosed of FTLD. For this purpose, a comparative 
study on cell proliferation, cell cycle profiles, and expression levels of key cell cycle 
regulatory proteins was performed. In addition, we investigated potential differences in 
the subcellular distribution of TDP-43 in control or PGRN+ lymphoblasts.  
Lymphoblasts from PGRN+ subjects show cell cycle progress modifications such as a 
decrease of cells in G1, an increased number of cells in S, together with altered 
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expression and phosphorylation of pRb and other proteins involved in cell cycle 
regulation. pRb protein functions as a molecular interface coupling the extracellular 
signals to the transcriptional machinery of the cells (Hatakeyama and Weinberg, 1995). 
When it is hypophosphorylated, pRb forms inhibitory complexes with members of E2F 
family of transcription factors (Chellappan et al., 1991).  Upon phosphorylation, pRb 
releases E2F, allowing them to promote the transcription of gene products necessary for 
cell cycle progression (Helin, 1998).  
pRb is sequentially phosphorylated by two sets of protein kinases, the cyclin 
D/CDK4/CDK6 and cyclin E/CDK2 complexes (Mittnacht, 1998). We did not observe 
differences in the levels of expression of cyclins D and E or in the kinases CDK4 and 
CDK2 between control and PGRN+ cells. However, a significant increase in cellular 
content in CDK6 protein was observed in PGRN+ lymphoblasts from FTLD patients. 
The cellular content of CDK inhibitors, either of the Cip/Kip family or the INK4 family 
was not influenced by PGRN deficiency. Therefore, the observed increase in the amount 
of hyperphosphorylated pRb in PGRN+ lymphoblasts seems to be the result of 
enhanced CDK6 activity.  
The activity and expression of CDK6 is amplified in a number of tumors (Brito-
Babapulle et al., 2002; Timmermann et al., 1997). Recently, it has been reported that 
CDK6 is repressed by TDP-43 (Ayala et al., 2008). The control of CDK6 expression 
mediated by TDP-43 involves GT repeats in the target gene sequence. The repeat traces 
are present once or twice in all of the larger introns. In contrast, introns in other human 
CDK genes, e.g., CDK4 and CDK2, are significantly shorter and lack (GT)n  (Ayala et 
al., 2008). Although these studies were performed in non-neuronal cells, increased CDK 
activity and pRb phosphorylation have linked to neuronal death in a number of cell and 
animal models of neurodegeneration (Greene et al., 2007; Nguyen et al., 2002).  Recent 
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studies have indicated that PGRN deficiency may result in a caspase-mediated cleavage 
of TDP-43 leading to mislocalization of TDP-43 to insoluble cytosolic fraction 
(Dormann et al., 2009; Zhang et al., 2007). Our results indicate that PGRN+ cells 
display a small but significant decrease in the nuclear content of TDP-43. Taken 
together, these observations suggest that a loss of nuclear TDP-43 function in repressing 
CDK6, may be involved in the increased pRb phosphorylation, and enhanced 
proliferative activity of PGRN+ cells.  
Our results show no differences in the proliferative activity and cellular content of 
CDK6 among lymphoblasts derived from FTLD patients presenting different clinical 
presentation (bv-FTD, PPA or CBS). Moreover, we had not observed significant 
differences between c.709-1G>A mutation carriers whether asymptomatic or with 
clinical signs of dementia. Since most of the asymptomatic carriers are younger than the 
patients (Table I), this finding suggests that cell cycle disturbances may be early 
manifestations of the disease. However, we observed that some PGRN+ individuals 
remain asymptomatic until advanced age. For example, only one of four brothers (age 
63-71), carriers of c.709-1G>A mutation was diagnosed of FTLD. This observation 
indicates the existence of modifiers factors (either genetic or environmental) in 
determining the onset of clinical disease.  
In summary, our results established a molecular link between mislocalization of TDP-
43 and increased CDK6 levels, pRb phosphorylation and proliferation of lymphoblasts 
from c.709-1G>A carriers. Assuming that the cell cycle disturbances reported here 
could be peripheral signs of the disease, our results suggest that neurons of c.709-1 
G>A mutation carriers are at high risk of entering an unscheduled cell cycle that would 
then drive them to death. It is suggested that therapeutical interventions aimed at 
ameliorating cell cycle progression activity may have a positive impact in FTLD. 
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TABLE I 
__________________________________________________________________ 
 Control               c.709-1 G>A carriers    
      (Asymptomatic)  FTDL Patients 
   n = 10                    n = 12                      n = 6 
__________________________________________________________________ 
Age (years) 524  534 653 
 
Age range       (31-70)         (35-72)           (54-70) 
 
Gender (Male/Female)      5/5                              6/6              0/6 
Control:  individuals  without  sign  of  neurological  degeneration;  c.709­1G>A:  PGRN 
Progranulin mutation; n: number of subjects. Values are expressed as mean±SE. 
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Legends to the F igures 
 
 
F ig. 1 
Proliferation of lymphoblasts f rom control subjects and PG RN mutation c.709-1 
G>A carriers. 
 (A) Immortalized lymphoblasts from control (open circles), PGRN mutation carriers 
asymptomatic (filled triangles), and carriers affected of FTLD (filled circles) were 
seeded at an initial density of 1 x 106 ml-1 and cultured for 3 days in RPMI medium 
containing 10% FBS. Everyday thereafter, samples were taken for cell counting. Values 
shown are the meanSE. (B) Scatter plots comparing proliferative activity between 
control and PGRN+ lymphoblasts after 72 h of serum stimulation. 
 
F ig. 2 
Cell cycle distr ibution of lymphoblasts in control subjects and PG RN mutation 
c.709-1 G>A car riers. 
The experimental conditions are identical to those described in the legend to Fig. 1. 
After 36 h of serum stimulation, cells were harvested, fixed, and analyzed by flow 
cytometry as described under Methods. Labels show areas of curve corresponding to 
G0/G1, S, and G2/M phases of cell cycle. The percentages of cells in the different phases 
of cell cycle are summarized below. Data shown are the meanSE of different 
experiments carried out with cell lines from six control subjects, asymptomatic or FTLD 
patients, carrying the PGRN c.709-1 G>A mutation, respectively. *p< 0.05 significantly 
different from control cells.  
 
 
 
  31 
F ig. 3 
Influence of the PG RN mutation C .709-1G>A on pRb levels and phosphorylation 
status. 
Immortalized lymphoblasts from control and PGRN mutation carriers, either 
asymptomatic or FTLD patients, were seeded at an initial density of 1 x 106 ml-1 and 
cultured in RPMI medium containing 10% FBS.  After 2 days of culture, cells were 
harvested and pRb was detected by immunobloting using a phospho-specific anti-pRb 
antibody. Two different experiments are shown. pp = the hyperphosphorylated form of 
the Rb protein. 
 
F ig. 4 
Cellular content of the Cyclin family of proteins involved in G1 regulation in 
serum-stimulate lymphoblasts f rom control or PG RN mutation carriers 
Cells were seeded at an initial density of 1 x 106 x ml-1. Two days after stimulation with 
10% FBS, samples were taken from each culture and total cellular proteins were 
separated on denaturing gels and immunobloted with the appropriate antibody as shown 
in the figure. Immunoreactive proteins were visualized with the enhanced 
chemiluminiscence detection system.  The densitometric data represent the meanSE 
for of at least 6 independent experiments carried out in cell lines derived from different 
individuals.  
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F ig. 5 
Cellular content of the C D K family of proteins involved in G1 regulation in serum-
stimulate lymphoblasts f rom control or PG RN mutation carriers. 
The experimental conditions were identical to those for Fig. 4. Representative 
immunoblots are shown, while below the densitometric analyses are presented. Data 
shown represent the mean±S.E. for at least 6 different experiments carried out in cell 
lines derived from different individuals. 
 
F ig. 6 
Cellular content of the C D K inhibitors involved in G1 regulation in serum-
stimulate lymphoblasts f rom control or PG RN mutation carriers. 
The levels of the CDK inhibitors either the Cip1/Kip1 or the INK families were 
determined after two days of serum stimulation. Representative immunoblots are 
presented. The densitometric data represent the meanSE for of at least 6 independent 
experiments carried out in cell lines derived from different individuals.  
 
 F ig. 7 
 Effect of increasing concentrations of sodium butyrate on proliferation of 
lymphoblasts f rom control and carriers of the C-709-1G>A PG RN mutation. 
(A) Lymphoblasts from control  and PGRN+ individuals were seeded at an initial 
density of 1 x 106 x ml-1 in RPMI medium containing 10%FBS, in the presence of 
increasing concentrations of sodium butyrate and cultured for 3 days.  Values shown are 
the mean±SE for, at least, 6 independent experiments carried out with different 
individuals.  *p <0.01 significantly different from control cells.; **p<0.01 significantly 
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different from PGRN+ lymphoblasts in the absence of sodium butyrate. (B) The effects 
of 10M sodium butyrate on CDK6 content and pRb phosphorylation status in control 
and PGRN+ lymphoblasts were evaluated 48 h after the addition of sodium butyrate.  
Five independent experiments were performed obtaining similar results. The mean 
values for CDK6/-actin ratios were 0.55±0.01, 0.81±0.09, and 0.84±0.07 in the 
absence of sodium butyrate and 0.53±0.1, 0.53±0.06, and 0.53±0.08 in the presence of 
sodium butyrate for control, asymptomatic PGRN+, and patients respectively. 
Differences found in PGRN+ cells incubated in the presence of sodium butyrate were 
statistically significant (p<0.05). Representative immunoblots are shown. pp: 
hyperphosphorylated form of pRb. 
 
F ig. 8 
Influence of the PG RN mutation c.709-1G> A on the subcellular localization of 
T DP-43 protein. 
(A) Lymphoblasts from control and PGRN+ individuals were seeded at an initial 
density of 1 x 106 x ml-1 and incubated during 48 h in RPMI medium containing 10% 
FBS. TDP-43 protein localization was assessed by confocal laser scanning microscopy. 
Cells were stained with anti-TDP-43 antibody followed by secondary antibody labeled 
with Alexa Fluor 488. DAPI and phaloidin were used for nuclear or cytosolic staining 
respectively. Merged images depict a predominant nuclear localization for TDP-43 
protein. Magnification (63X). (B) Cells were harvested after 48 h of serum stimulation 
and fractionated to determine by immunoblot the localization of of TDP-43. Antibodies 
to -tubulin and to lamin B1 were used as control of purity and loading of cytoplasmic 
and nuclearprotein extracts, respectively. Representative immunoblots are shown, 
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whereas the densitometric analysis is presented below. Data represent meanSE for at 
least 6 experiments. *p<0.05 significantly different from control lymphoblasts. 
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